Citadel Advisors’s Lux Health Tech Acquisition Corp. Class A Common Stock LUXA Stock Holding History

Citadel Advisors’s Portfolio LUXA Stock Details LUXA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-39,525	Closed	-$393K	–	14135
2022 Q2	$391K	Buy	+39,525	New	+$390K	﹤0.01%	9191
2022 Q1	–	Sell	-23,329	Closed	-$229K	–	15112
2021 Q4	$229K	Buy	23,329 +11,497	+97%	+$113K	﹤0.01%	11579
2021 Q3	$116K	Buy	+11,832	New	+$117K	﹤0.01%	12690

Citadel Advisors's LUXA Position: Q3 2022 in Review

Citadel Advisors sold out of Lux Health Tech Acquisition Corp. Class A Common Stock (LUXA) in Q3 2022, closing a stake of 39,525 shares — an estimated $393K sold.

Citadel Advisors first reported a position in LUXA in Q3 2021 and held it in 3 quarters. The position peaked at $391K in Q2 2022. 72 funds tracked by Wall St. Rank hold LUXA as of Q3 2022.

Citadel Advisors reported no remaining Lux Health Tech Acquisition Corp. Class A Common Stock position as of Q3 2022 after selling out during the quarter.
Citadel Advisors sold 39,525 Lux Health Tech Acquisition Corp. Class A Common Stock shares in Q3 2022, an estimated $393K.
Citadel Advisors first reported a position in Lux Health Tech Acquisition Corp. Class A Common Stock in Q3 2021 and held it in 3 quarters.
Citadel Advisors's Lux Health Tech Acquisition Corp. Class A Common Stock position peaked at $391K in Q2 2022.
72 funds tracked by Wall St. Rank held Lux Health Tech Acquisition Corp. Class A Common Stock as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.